<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289690</url>
  </required_header>
  <id_info>
    <org_study_id>M14-361</org_study_id>
    <secondary_id>2014-001764-35</secondary_id>
    <nct_id>NCT02289690</nct_id>
  </id_info>
  <brief_title>Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to assess the efficacy of veliparib (ABT-888) in combination with
      carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED
      SCLC). ED SCLC is defined herein as any SCLC except a disease confined to the hemithorax of
      origin, with or without the involvement of regional lymph nodes, including ipsilateral and
      contralateral mediastinal, ipsilateral and contralateral mediastinal, and ipsilateral
      supraclavicular nodes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with carboplatin and etoposide</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose of veliparib (ABT-888) in combination with carboplatin and etoposide</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events during maintenance veliparib monotherapy at 400 mg twice daily (BID)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Veliparib and carboplatin and etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veliparib in combination with carboplatin and etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Varying doses administered on Days -2 to 5 in a 21-day cycle</description>
    <arm_group_label>Veliparib and carboplatin and etoposide</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered on Day 1 via intravenous infusion in a 21-day cycle</description>
    <arm_group_label>Veliparib and carboplatin and etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Administered on Days 1 to 3 via intravenous infusion in a 21-day cycle</description>
    <arm_group_label>Veliparib and carboplatin and etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject with histologically or cytologically confirmed extensive-stage disease SCLC
             which is newly diagnosed and chemotherapy naive

          2. Phase 1 ONLY: histologically or cytologically confirmed advanced/metastatic solid
             tumors for which carboplatin/etoposide treatment is considered appropriate.

          3. Subject in Phase 2 only: must have measurable disease per RECIST 1.1.

          4. Subjects with ED SCLC must consent to provide available archived formalin fixed
             paraffin embedded (FFPE) tissue sample of SCLC lesion (primary or metastatic) for
             central review and biomarker analysis.

          5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1.

          6. Subject must have adequate hematologic, renal and hepatic function.

        Exclusion Criteria:

          1. Phase 1 ONLY: Subject has had any prior anti-cancer therapy other than:

             Hormonal, non-myelosuppressive, biologic, targeted, or immune therapy (must be
             completed ≥ 4 weeks prior to Cycle 1 Day -2).

             One line of cytotoxic chemotherapy (must be completed ≥ 4 weeks prior to Cycle 1 Day
             -2).

             Adjuvant/neoadjuvant radiotherapy (must be completed ≥ 12 months prior to Cycle 1 Day
             -2, with field not involving &gt; 10% of bone marrow reserve).

          2. Phase 2 ONLY: Subject has had any prior chemotherapy, radiotherapy, investigational
             anti-cancer agents or biologic therapy for the disease under study. Single non-target
             lesion irradiation with intent of symptom palliation is allowed if ≥ 4 weeks prior
             Cycle 1 Day -2.

          3. Subject has current central nervous system (CNS) or leptomeningeal metastases or
             history of CNS or leptomeningeal metastases.

          4. Subject has a history of seizures within 12 months of Cycle 1 Day-2 or diagnosed
             neurological condition placing subject at the increased risk of seizures.

          5. Subject has received anti-cancer Chinese medicine or anti-cancer herbal remedies
             within 14 days prior to Cycle 1 Day-2.

          6. Subject has had major surgery within 6 weeks prior to Cycle 1 Day-2 (subjects must
             have completely recovered from any previous surgery prior Cycle 1 Day-2).

          7. Subject has clinically significant and uncontrolled major medical condition(s)
             including but not limited to:

               -  Uncontrolled nausea/vomiting/diarrhea;

               -  Active uncontrolled infection;

               -  History of hepatitis B (HBV) with surface antigen (HBsAg) positivity within 3
                  months prior to the date of informed consent for this study (if no test has been
                  performed within 3 months, it must be done at screening);

               -  History of hepatitis C (HCV) with HCV RNA positivity within 3 months prior to
                  the date of informed consent for this study (if no test has been performed
                  within 3 months it must be done at screening);

               -  Symptomatic congestive heart failure (NYHA class ≥ II);

               -  Unstable angina pectoris or cardiac arrhythmia (except atrial fibrillation);

               -  Psychiatric illness/social situation that would limit compliance with study
                  requirements;

               -  Any other medical condition, which in the opinion of the Investigator, places
                  the subject at an unacceptably high risk for toxicities.

          8. The subject has a history of another active cancer within the past 3 years except
             cervical cancer in situ, in situ carcinoma of the bladder, squamous or basal cell
             carcinoma of the skin or another in situ cancer that is considered cured by the
             investigator (e.g., in situ prostate cancer, breast DCIS).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Komarnitsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsey Rosenwinkel, BS</last_name>
    <phone>847-937-6985</phone>
    <email>lindsey.rosenwinkel@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Hetman, BS</last_name>
    <phone>847-938-5745</phone>
    <email>robert.hetman@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129127</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129127, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129220</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129220, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141682</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141682, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137088</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137088, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129214</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129214, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129216</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129216, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129213</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129213, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132883</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132883, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131252</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 131252, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149830</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149830, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134719</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131251</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 131251, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130302</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130302, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130301</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130301, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 14, 2016</lastchanged_date>
  <firstreceived_date>November 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Veliparib</keyword>
  <keyword>PARP - Poly (ADP) ribose polymerase</keyword>
  <keyword>ABT-888</keyword>
  <keyword>Extensive Stage Smal Cell Lung Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
